| Title |
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
|
|---|---|
| Published in |
Annals of Hematology, July 2014
|
| DOI | 10.1007/s00277-014-2152-7 |
| Pubmed ID | |
| Authors |
Alberto Alvarez-Larrán, Luz Martínez-Avilés, Juan Carlos Hernández-Boluda, Francisca Ferrer-Marín, María Luisa Antelo, Carmen Burgaleta, M. Isabel Mata, Blanca Xicoy, Alejandra Martínez-Trillos, M. Teresa Gómez-Casares, M. Antonia Durán, Bárbara Marcote, Agueda Ancochea, Alicia Senín, Anna Angona, Montse Gómez, Vicente Vicente, Francisco Cervantes, Beatriz Bellosillo, Carles Besses |
| Abstract |
Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited. Busulfan is effective as first-line therapy, but there is scarce information on this drug as second-line treatment. The efficacy of busulfan in patients with advanced PV or ET refractory or intolerant to hydroxyurea was assessed in 36 patients (PV n = 15, ET n = 21) treated for a median of 256 days. Complete hematological response (CHR) was achieved in 83 % of patients, after a median time of 203 days (range 92-313). The probability of sustained CHR at 1 and 2 years was 87 and 62 %, respectively. Time to CHR was shorter in patients treated with ≥14 mg of busulfan per week than with lower doses (141 versus 336 days, p = 0.01). Partial molecular response was achieved in three out of nine (33 %) patients. Busulfan was stopped in 27 patients (75 %) due to CHR achievement in 18 cases (67 %), hematological toxicity in 8 cases (30 %), and disease transformation in 1 case. With a median follow-up of 721 days, six patients have died, with the probability of survival at 2 years being 85 %. The probability of thrombosis at 2 years was 11 %. Transformation into acute leukemia or myelodysplastic syndrome was observed in three cases, all of them in a JAK2V617F-negative clone carrying additional mutations. Busulfan, at a dose of 2 mg/day, is an effective option for elderly patients with PV or ET who fail to hydroxyurea, but a significant rate of transformation was observed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 3% |
| Unknown | 59 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 11% |
| Student > Master | 7 | 11% |
| Student > Doctoral Student | 5 | 8% |
| Student > Bachelor | 5 | 8% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 13 | 21% |
| Unknown | 19 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 38% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Nursing and Health Professions | 3 | 5% |
| Environmental Science | 2 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 22 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2014.
All research outputs
#20,232,430
of 22,758,248 outputs
Outputs from Annals of Hematology
#1,702
of 2,164 outputs
Outputs of similar age
#192,117
of 227,688 outputs
Outputs of similar age from Annals of Hematology
#24
of 29 outputs
Altmetric has tracked 22,758,248 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,164 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,688 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.